

HETEROCYCLES, Vol. 65, No. 6, 2005, pp. 1295 - 1309

Received, 27th September, 2004, Accepted, 6th April, 2005, Published online, 8th April, 2005

SYNTHESIS AND CONVERSION OF 3-(2-HYDROXYTHIOBENZAMIDO)BENZO[*b*]FURANS

Detlef Briel

Institute of Pharmacy, Faculty of Biosciences, Pharmacy, and Psychology,
University of Leipzig, Brüderstrasse 34, D-04103 Leipzig, Germany
briel@rz.uni-leipzig.de

Abstract - A simple method for the introduction of a 2-arylbenzofuran-3-yl residue at the nitrogen atom of 2-hydroxythiobenzamide is described. Thereby *N*-(2-arylbenzofuran-3-yl)-2-hydroxythiobenzamides (**4**) were obtained which undergo an oxygen-sulfur position exchange when they were heated in acetic acid yielding the isomeric *N*-(2-thioarylbenzofuran-3-yl)-2-hydroxybenzamides (**6**).

INTRODUCTION

A large number of substituted *N*-aryl-2-hydroxy(thio)benzamide derivatives are used as drugs with different indications (e.g. as antipyretic, antiinflammatory or antibacterial drugs).¹ In contrast thereto the pharmacological actions of *N*-benzofuryl-2-hydroxy(thio)benzamide derivatives are previously unknown. On the other hand, a number of 2-aryl-3-aminobenzo[*b*]furans are known to be active as analgesic,² antiinflammatory³ and antiallergic⁴ compounds; 2-aryl-3-thiocarbonylbenzo[*b*]furans were described to have antiinflammatory properties.³ These facts lead one to suppose that the previously unknown 2-aryl-3-(2-hydroxythiobenzamido)benzo[*b*]furans may be a class of pharmacologically relevant compounds.

RESULTS AND DISCUSSION


The dithiazole (**2**) which is prepared by oxidation of 2-hydroxythiobenzamide (**1**)^{5,6} can be alkylated at the phenolic hydroxyl group.⁷ Using bromoacetylaryl derivatives (BrCH₂COAr) with Et₃N in DMF the alkylation leads to the formation of the phenolic ethers (**3**) (Scheme 1) which were obtained in yields of 73-96% as dark violet crystals, only slightly soluble in the common solvents.

When the suspension of **3** in sodium methoxide/MeOH was refluxed for a few minutes a clear

solution resulted from which the hydroxythiobenzamidobenzofurans (**4**) precipitated after acidification. This reaction can be explained as a nucleophilic attack of the lateral acidic methylene moiety at the electrophilic dithiazole-C5-atom of **3**. After ring opening and extrusion of one sulfur atom the products (**4**) are formed.

Alternatively an attack of sodium methoxide is possibly the first step of the ring opening reaction, however no evidence is given for this course of the reaction.

A possible role of the benzoxazines (**7**) (isomeres of **4**) as intermediates or reaction products⁸ could be excluded by the spectroscopic data that indicated no appearance of **7**.



Scheme 1

The type of the synthesis belongs to those benzo[*b*]furan preparations in which an *ortho*-carbofunctionalized phenol is reacting with an acceptor-substituted halomethane (HalCH₂CY).⁹

Thereby an *O*-alkylation is the first step of the reaction. The resulting aryl ether possesses an activated nucleophilic methylene group that attacks the *ortho*-carbon substituent leading to the formation of the C2-C3 bond of the resulting benzofuran (Figure 1). Benzofurans prepared by this way always bear an acceptor group (CY) at the C2. The substituent at the C3 atom can be

determined by the choice of the *ortho*-carbo function of the phenolic educt.⁹⁻¹¹ When a nitrile (2-hydroxybenzotrile) is used, for example, benzofurans with an amino function ($Z = \text{NH}_2$) are obtained.^{12,13,19}

In the syntheses described in this report the *ortho*-carbo function is a part of a dithiazole cycle. The benzofuran is formed as the product of a ring transformation during the course of which the 2-hydroxythiobenzamido substituent at the C3 is generated.





Figure 1

The yellow hydroxythiobenzamidobenzofurans (**4**) were converted into the isomeric dark brown thioaroylbenzofurans (**6**) by refluxing in acetic acid. A possible intermediate of this conversion could be the thiazinium salt (**5**) that may undergo a ring opening to form **6** after addition of water at the C2. Considering the reactivity of other 1,3-thiazinium salts, the attack of nucleophiles at the thiazine-C2-atom¹⁴ as well as at the thiazine-C4-atom¹⁵⁻¹⁷ is probable. Possibly, the products of a nucleophilic reaction at the C2 are formed as thermodynamically stable final compounds. Thereby the phenolic hydroxy group may have an influence on the course of the reaction.

The structures of **4a** and **6a** were confirmed by the ¹H NMR (H-COSY) and ¹³C NMR spectra (HMQC, HMBC). For an additional structural proof **4a** and **6a** were treated with H₂O₂/NaOH. Thereby the sulphur atom of the respective thioamide or thioketone group was replaced by oxygen. In both cases the benzofuran (**9**) was the resulting product (Scheme 2). Compound (**9**)



Scheme 2

was also obtained by an alternative synthesis. Therefore the benzofuran (**8**) was prepared according to Gewald and Jänsch¹⁹ followed by subsequent conversion with 2-acetoxybenzoyl-chloride/ NaOH.

The comparison of the NMR signals of the compounds listed in Table 1 reveal the following results: The peaks of the acylamide-C-atoms of **6a** (164.96) and **9** (165.75) have almost the same chemical shifts. The analogous peak of the 2-hydroxybenzamide (**11**) has a shift of 172.42 ppm. The chemical shifts of the thioacylamide-C-atoms of **4a** (196.94) and the 2-hydroxythiobenzamide (**10**) (196.90) are identical. As well, the signals of the ketone-C-atoms of **4a**, **9** and **8** have nearly the same chemical shifts.

Table 1. Chemical shifts of the carbonyl- and thiocarbonyl-C-atoms of **4a**, **6a**, **8**, **9**, **10** and **11**

	-NH-CO-	-NH-CS-	-CO-C ₆ H ₅	-CS-C ₆ H ₅
4a		196.94	183.86	
6a	164.96			213.25
8			180.78	
9	165.75		183.24	
2-hydroxythiobenzamide (10)		196.90		
2-hydroxybenzamide (11)	172.42			

The identity of the thioketone-atom of **6a** (213.25) was checked by the respective cross peaks (correlation with C-H₂' and C-H₆'': 7.72; HMBC). The acylamide-C-atom of **6a** (164.96) is characterized by a correlation with the CH-6' (7.98) and a weak correlation with NH (12.31). In the ¹H NMR spectra of **6a** the position of the peaks of the NH and the OH group at 11.64 and





Figure 2

12.31 is an indication for the appearance of hydrogen bridge linkages. Dissolution experiments provided evidence that these hydrogen bonds are intramolecular (Figure 2).

The MS spectra of the benzofurans (**4**) and (**6**) exhibit the molecular peaks with an intensity of 10-73 % (Table 2). The main process of the fragmentation is the α -cleavage of the compounds into an aminothioaroylbenzofuran ion (**AC**, Y=S, 40-100 %; Scheme 3) and a 2-hydroxybenzoyl fragment ion (**B**, X=O, 41-100 %). This fragmentation is observed in the case of hydroxybenzoylbenzofurans (**6**) as well as in the case of the hydroxythiobenzoylbenzofurans (**4**)



Scheme 3

Table 2. MS spectral fragmentation of the hydroxy(thio)benzoylbenzofurans (**4**) and (**6**) [% rel.int.]

	X	Y	M ⁺	AC	B	AC+H ^(a)	B	C	C	D	E
				(Y=S)	(X=O)	(Y=O)	(X=S)	(Y=O)	(Y=S)		
4a	S	O	32	100	50	18	-	44	-	48	17
4b	S	O	28	100	93	21	-	13	8	47	7
4c	S	O	20	62	100	20	-	11	-	19	9
4d	S	O	20	100	41	10	-	5	8	34	10
4e	S	O	73	53	33	4	-	100	-	20	20 ^(b)
6a	O	S	27	100	52	4	-	-	-	48	2
6b	O	S	10	47	100	15	-	5	7	19	7
6c	O	S	27	40	100	21	-	5	-	28	7
6d	O	S	25	100	43	9	-	-	7	37	8
6e	O	S	37	100	55	5	-	8	8	19	5

^(a) no appearance of an **AC** fragment

^(b) M⁺-OH instead of M⁺-O

leading to the supposition that under MS conditions a conversion of **4** into **6** is induced.

The appearance of an isomeric fragmentation in the case of **4a** and **6a** under formation of **AB** (X=O) and **C** (Y=S) could be excluded by highly resolution MS spectra. A cleave-off of hydroxythiobenzoyl radical with formation of an aminoaroylbenzofuran ion (**AC**+H, Y=O), which could be expected in the case of the hydroxythiobenzoylbenzofurans (**4**), was detected in only small amounts. This fragment was also observed with a low intensity in the MS spectra of **6** (4-21 %) indicating that under MS conditions a slight conversion of **6** into **4** seems to take place.

All the compounds (**4**) generate aroyl fragment ions (**C**, Y=O, 5-100 %). The intensity of this fragmentation is higher in the case of **4** than in the case of the compounds (**6**) and proves to be the striking difference between the MS spectra of these isomers. In contrast, thereto the formation of a thioaroyl fragment ion (**C**, Y=S) was observed to an only small extend.

Another fragmental ion - [(M⁺)-HS] (19-48 %) - is also visible in all the MS spectra of **4** and **6**. This is possibly due to the formation of an oxazinium cation (**D**).

A remarkable observation in all the spectra of **4** and **6** is the release of oxygen leading to the formation of the fragment ion [(M⁺)-O] (E, 5-17 %; high resolution MS spectrum in the case of **4a** and **6a**; M-OH in the case of **4e**, 20 %, high resolution). This fragmentation is known from substances that are able to release oxygen (e.g. nitro compounds or sulfoxides).¹⁸ For compounds with keto or carbonamide structures it is rather exceptional.

To suppress thermally induced conversions during the MS spectrometry additional spectra of **4a** and **6a** were recorded using a cold ionization source. However, no differences to the usual spectra of these compounds could be found.

EXPERIMENTAL

Melting points are uncorrected. IR spectra were measured with a Perkin Elmer 16 PC FTIR spectrophotometer. ¹H NMR spectra and ¹³C NMR spectra were recorded on a Varian Gemini 300 operating at 300 MHz for ¹H and 75 MHz for ¹³C and a Bruker DRX-600 Avance operating at 600,13 MHz and 150,91 MHz for ¹³C. MS spectra were recorded on a JEOL JMS-D 100 spectrometer (EI, 70eV), resp. Finnigen MAT 8230. The temperature of the ion source was 250 °C; in measurements with a cold ionization source the temperature was 130 °C. ESI-HRMS spectra were recorded on a Bruker Daltonics 7T Apex II FT-ICR-MS.

Substituted 6-[5-(2-hydroxyphenyl)-1,2,4-dithiazol-3-ylidene]-2,4-cyclohexadien-1-one (**3**)

General procedure

To a stirred solution of Et₃N (1 mL, 7.2 mmol) in DMF (10 mL) **2**^{5,6} (1.0 g, 3.5 mmol) was

added. After stirring for 2 min at rt powdered BrCH_2COAr (7 mmol) was added in one portion. The mixture was stirred for further 5 min and the precipitated product was filtered off by suction. The collected crystals were washed with MeOH. (All the resulting compounds were only very slightly soluble in the common solvents. For this reason it was not possible to record NMR-spectra).

6-[5-(2-Phenacyloxyphenyl)-1,2,4-dithiazol-3-ylidene]-2,4-cyclohexadien-1-one (3a)

Starting from $\text{BrCH}_2\text{COC}_6\text{H}_5$ (1.4 g; 7 mmol). Yield 1.31 g (92%). dark violet crystals (AcOH); mp 165-170 °C (lit.,⁷ 158-165 °C). IR (KBr): $\nu = 3060, 2925, 1692, 1609 \text{ cm}^{-1}$. MS (EI): m/z (%) = 405 (M^+ , 1), 287 (37), 105 (100). MS (EI-HRMS): m/z (%) = 405.05039(7)(M^+) ($\text{C}_{22}\text{H}_{15}\text{NO}_3\text{S}_2$ requires 405.04928). Anal. Calcd for $\text{C}_{22}\text{H}_{15}\text{NO}_3\text{S}_2$: C, 65.17; H, 3.73; N, 3.45; S, 15.82. Found: C, 65.21; H, 3.74; N, 3.26, S, 16.01.

6-{5-[2-(4-Chlorophenacyloxy)phenyl]-1,2,4-dithiazol-3-ylidene}-2,4-cyclohexadien-1-one (3b)

Starting from $\text{BrCH}_2\text{COC}_6\text{H}_4\text{-4-Cl}$ (1.63 g; 7 mmol). Yield 1.39 g (90%). dark violet crystals (after boiling with AcOH and subsequent separation by filtration); mp 238-240 °C. IR (KBr): $\nu = 2924, 2854, 1696, 1609 \text{ cm}^{-1}$. MS (EI): m/z (%) = 439 (M^+ , 3), 287 (80), 139 (100). Anal. Calcd for $\text{C}_{22}\text{H}_{14}\text{NO}_3\text{ClS}_2$: C, 60.06; H, 3.21; N, 3.18, S, 14.58. Found: C, 60.36; H, 3.15; N, 3.11, S, 14.39.

6-{5-[2-(3-Nitrophenacyloxy)phenyl]-1,2,4-dithiazol-3-ylidene}-2,4-cyclohexadien-1-one (3c)

Starting from $\text{BrCH}_2\text{COC}_6\text{H}_4\text{-3-NO}_2$ (1.71 g; 7 mmol). Yield 1.51 g (96%). dark violet crystals (AcOH); mp 178-183 °C (lit.,⁷ 178-183 °C). IR (KBr): $\nu = 3086, 2925, 1699, 1609 \text{ cm}^{-1}$. MS (EI): m/z (%) = 450 (M^+ , 2), 298 (76), 287 (65), 150 (63). Anal. Calcd for $\text{C}_{22}\text{H}_{14}\text{N}_2\text{O}_5\text{S}_2$: C, 58.66; H, 3.13; N, 6.22, S, 14.24. Found: C, 58.69; H, 3.19, N, 6.16; S, 14.36.

6-{5-[2-(2-Naphth-2-yl-2-oxoethoxy)phenyl]-1,2,4-dithiazol-3-ylidene}-2,4-cyclohexadien-1-one (3d)

Starting from $\text{BrCH}_2\text{COC}_{10}\text{H}_7$ (1.74 g; 7 mmol). Yield 1.39 g (87%). dark violet crystals (AcOH); mp 229-232 °C. IR (KBr): $\nu = 3057, 2924, 1683, 1609 \text{ cm}^{-1}$. MS (EI): m/z (%) = 455 (M^+ , 5), 302

(40), 287 (100), 155 (82). Anal. Calcd for $C_{26}H_{17}NO_3S_2$: C, 68.55; H, 3.76; N, 3.07; S, 14.08. Found: C, 68.37; H, 3.72; N, 2.96; S, 14.27.

6-{5-[2-(2-Thien-2-yl-2-oxoethoxy)phenyl]-1,2,4-dithiazol-3-ylidene}-2,4-cyclohexadien-1-one (3e)

Starting from $BrCH_2COC_4H_3S$ (1.44 g; 7 mmol). Yield 1.05 g (73%). dark violet crystals (AcOH); mp 201-203 °C. IR (KBr): $\nu = 3072, 2924, 1671, 1609\text{ cm}^{-1}$. MS (EI): m/z (%) = 411 (M^+ , 14), 287 (61), 111 (100). Anal. Calcd for $C_{20}H_{13}NO_3S_3$: C, 58.37; H, 3.18, N, 3.40; S, 23.38. Found: C, 58.39; H, 3.22; N, 3.30; S, 23.40.

N-(2-Aroylbenzo[b]furan-3-yl)-2-hydroxythiobenzamides (4)

General Procedure

3 (1.0 g; crude product) was added to a 5M NaOMe-solution in MeOH (5 mL). The mixture was refluxed for 5 min. After cooling to rt the solution was acidified with 1M HCl. The oily precipitate was repeatedly rubbed with water until the substances began to crystallize.

N-(2-Benzoylbenzo[b]furan-3-yl)-2-hydroxythiobenzamide (4a)

Starting from **3a** (1.0 g, 2.5 mmol). Yield 0.68 g (73%). yellow needles (benzene); mp 156-160 °C. IR (KBr): $\nu = 1610\text{ cm}^{-1}$. 1H NMR (DMSO- d_6 , H-COSY): $\delta = 6.87$ (br dd, 1H, CH-5'), 6.97 (br d, 1H, CH-3'), 7.33 (br dd, 1H, CH-4'), 7.41 (br dd, 1H, CH-5), 7.54 (br dd, 2H, CH-3'', CH-5''), 7.59 (br dd, 1H, CH-6), 7.66 (m, 2H, CH-6', CH-4''), 7.79 (br d, 1H, CH-4), 7.79 (br d, 1H, CH-7), 7.98 (br d, 2H, CH-2'', CH-6''), 10.89 (br s, 1H, NH), 12.02 (br s, 1H, OH). Broad signals because of tautomerism, the giving of coupling constants is therefore not possible. ^{13}C NMR (DMSO- d_6 , HMQC, HMBC): $\delta = 112.68$ (C-7), 116.95 (C-3'), 118.88 (C-5'), 123.43 (C-4), 123.57 (C-5), 126.69, 127.58, 143.82 (C-2, C-3, C-3a, C1'), 128.40 (C-3'', C-5''), 128.57 (C-6), 129.08 (C-2'', C-6''), 131.25 (C-6'), 132.20 (C-4'), 133.15 (C4''). 136.72 (C-1''), 153.39, 153.97 (C-2', C7a), 183.86 (CO), 196.94 (CS). MS (EI-HRMS): m/z (%) = 373.0806 (32)(M^+) ($C_{22}H_{15}NO_3S$ requires 373.07725), 357.08849 (17)($M-O$) $^+$ ($C_{22}H_{15}NO_2S$ requires 357.08234), 340.10064 (48)($M-SH$) $^+$ ($C_{22}H_{14}NO_3$ requires 340.09735), 280.04343 (8)($M-C_6H_5O$) $^+$ ($C_{16}H_{10}NO_2S$ requires 280.04321), 268.04332 (6)($M-C_7H_5O$) $^+$ ($C_{15}H_{10}NO_2S$ requires 268.04321), 252.04807 (100)($M-C_7H_5O_2$) $^+$ ($C_{15}H_{10}NOS$ requires 252.0483) ($C_{15}H_{10}NO_3$ requires 252.06605), 237.07734 (18)($M-C_7H_4OS$) $^+$ ($C_{15}H_{11}NO_2$ requires 237.07896) ($C_{15}H_9OS$ requires 237.0374), 220.07489 (4), 121.0285 (50)($C_7H_5O_2$ requires 121.02895)(C_7H_5S requires

121.0112), 105.0351 (44)(C₇H₅O requires 105.03404), 93.03454 (12)(C₆H₅O requires 93.03404). MS (ESI-HRMS)(positive): $m/z = 396.06650$ (M+Na)⁺ (C₂₂H₁₅NO₃NaS requires 396.06703). Anal. Calcd for C₂₂H₁₅NO₃S: C, 70.76; H, 4.05; N, 3.75. Found: C, 70.72; H, 4.07, N, 3.68.

N-[2-(4-Chlorobenzoyl)benzo[*b*]furan-3-yl]-2-hydroxythiobenzamide (4b)

Starting from **3b** (1.0 g, 2.3 mmol). Yield 0.75 g (80%). yellow needles (benzene); mp 118 °C (decomp). IR (KBr): $\nu = 1611$ cm⁻¹. ¹H NMR (DMSO-*d*₆): $\delta = 6.88$ -7.96 (m, 12H, aromat.), 11.0-12.3 (very br, NH, OH). ¹³C NMR (DMSO-*d*₆): $\delta = 113.40$, 117.45, 119.43, 124.25, 124.36, 129.20, 131.45, 132.95, 136.71, 154.22, 173.59 (CO), 197.41 (CS). MS (EI): m/z (%)= 407 (M⁺, 28), 391 (M-O)⁺ (7), 374 (M-SH)⁺ (47), 286 (M-C₇H₅O₂)⁺ (100), 271 (M-C₇H₄OS)⁺ (21), 155 (C₇H₄ClS)⁺ (8), 139 (C₇H₄ClO)⁺ (13), 121 (C₇H₅O₂)⁺ (93), 93 (C₆H₅O)⁺ (20). Anal. Calcd for C₂₂H₁₄NO₃ClS: C, 64.79; H, 3.46, N, 3.43. Found: C, 64.69; H, 3.51, N, 3.43.

N-[2-(3-Nitrobenzoyl)benzo[*b*]furan-3-yl]-2-hydroxythiobenzamide (4c)

Starting from **3c** (1.0 g, 2.2 mmol). Yield 0.56 g (61%). yellow needles (benzene); mp 116-119 °C (decomp). IR (KBr): $\nu = 1611$ cm⁻¹. ¹H NMR (DMSO-*d*₆): $\delta = 6.87$ -8.61 (m, 12H, aromat.), 10.5-12.3 (very br, NH,OH). ¹³C NMR (DMSO-*d*₆): $\delta = 112.62$, 116.62, 118.68, 123.04, 123.50, 123.75, 126.80, 128.28, 128.94, 130.05, 131.42, 132.18, 134.87, 147.54, 153.60, 154.46, 177.40 (CO), 196.67 (CS). MS (EI): m/z (%)= 418 (M⁺, 20), 402 (M-O)⁺ (9), 385 (M-SH)⁺ (19), 298 (M-C₇H₄O₂)⁺ (32), 297 (M-C₇H₅O₂)⁺ (62), 282 (M-C₇H₄OS)⁺ (20), 251 (15), 121 (C₇H₅O₂)⁺ (100), 150 (C₇H₄NO₃)⁺ (11), 93 (C₆H₅O)⁺ (21). Anal. Calcd for C₂₂H₁₄N₂O₅S. C, 63.15; H, 3.37; N, 6.69. Found: C, 62.88; H, 3.40; N, 6.70.

N-[2-(Naphth-2-oyl)benzo[*b*]furan-3-yl]-2-hydroxythiobenzamide (4d)

Starting from **3d** (1.0 g, 2.2 mmol). Yield 0.88 g (95%). yellow needles (benzene); mp beginning at 150 °C (decomp). IR (KBr): $\nu = 1605$ cm⁻¹. ¹H NMR (DMSO-*d*₆): $\delta = 6.70$ -8.72 (m, 15H, aromat.), 10.5-12.4 (very br, NH,OH). ¹³C NMR (DMSO-*d*₆): $\delta = 112.63$, 116.52, 118.29, 123.14, 123.41, 123.58, 124.58, 126.74, 127.57, 127.98, 128.28, 128.48, 128.97, 129.65, 130.92, 131.87, 134.41, 134.47, 134.84, 153.52, 155.15, 183.76 (CO), 196.05 (CS). MS (EI): m/z (%)= 423 (M⁺, 20), 407 (M-O)⁺ (10), 390 (M-SH)⁺ (34), 302 (M-C₇H₅O₂)⁺ (100), 287 (M-C₇H₄OS)⁺ (10), 270 (13), 171 (C₁₁H₇S)⁺ (8), 160 (7), 155 (C₁₁H₇O)⁺ (5), 139 (7), 121

(C₇H₅O₂)⁺ (41), 93 (C₆H₅O)⁺ (13). Anal. Calcd for C₂₆H₁₇NO₃S: C, 73.74, H, 4.05; N, 3.31. Found: C, 73.69; H, 4.07, N, 3.33.

N-[2-(Then-2-oyl)benzo[*b*]furan-3-yl]-2-hydroxythiobenzamide (4e)

Starting from **3e** (1.0 g, 2.4 mmol). Yield 0.69 g (76%). yellow needles (benzene); mp beginning at 130 °C (decomp). IR (KBr): $\nu = 1612 \text{ cm}^{-1}$. ¹H NMR (DMSO-*d*₆): $\delta = 6.98\text{--}8.43$ (m, 11H, aromat.), 10.5-12.7 (br, NH, OH). ¹³C NMR (DMSO-*d*₆): $\delta = 112.89, 116.86, 119.13, 123.20, 123.56, 123.98, 125.95, 128.67, 128.84, 129.21, 132.08, 132.69, 135.06, 136.58, 142.09, 142.77, 153.25, 154.49, 174.65$ (CO), 196.42 (CS). MS (EI-HRMS): m/z (%) = 379.03252 (73)(M⁺), (C₂₀H₁₃NO₃S₂ requires 379.03368), 362.02695 (20)(M-OH)⁺ (C₂₀H₁₂NO₂S₂ requires 362.03095), 346.05379 (20)(M-HS)⁺ (C₂₀H₁₂NO₃S requires 346.0493), 268.0405 (87)(M-C₅H₃OS)⁺ (C₁₅H₁₀NO₂S requires 268.04323), 257.99859 (53)(M-C₇H₅O₂)⁺ (C₁₃H₈NOS₂ requires 258.00473), 243 (4)(M-C₇H₄OS)⁺, 242 (13), 226 (7), 121.02743 (33)(C₇H₅O₂)⁺ (requires 121.02895), 110.98942 (100)(C₅H₃OS)⁺ (requires 110.99046). Anal. Calcd for C₂₀H₁₃NO₃S₂: C, 63.31, H, 3.45, N, 3.69. Found. C, 63.39; H, 3.41; N, 3.65.

N-(2-Thioaroylbenzo[*b*]furan-3-yl)- 2-hydroxybenzamide (6)

General Procedure

Powdered **4** (100 mg) was added to acetic acid (2 mL). The mixture was refluxed for 10 min and the solvent was evaporated i.vac.. After cooling to rt the precipitate was collected.

N-(2-Thiobenzoylbenzo[*b*]furan-3-yl)-2-hydroxybenzamide (6a)

Starting from **4a** (100 mg, 0.268 mmol). Yield 93 mg (93%). dark brown crystals (AcOH); mp 178-180 °C. IR (KBr): $\nu = 1658, 1593 \text{ cm}^{-1}$. ¹H NMR (DMSO-*d*₆, H-COSY): $\delta = 7.01$ (dd, J = 7.8, 7.8 Hz, 1H, CH-5'), 7.07 (d, J = 8.4 Hz, 1H, CH-3'), 7.38 (dd, J = 7.8, 7.7 Hz, 1H, CH-5), 7.47 (dd, J = 7.8, 7.7 Hz, 2H, CH-3'', CH-5''), 7.50 (dd, J = 7.8, 7.8 Hz, 1H, CH-4'), 7.57 (m, 1H, CH-4''), 7.62 (d, J = 8.4 Hz, 1H, CH-7), 7.67 (dd, J = 7.3, 7.1 Hz, 1H, CH-6), 7.72 (d, J = 7.8 Hz, 2H, CH-2'', CH-6''), 7.98 (m, 1H, CH-6'), 8.12 (d, J = 8.4 Hz, 1H, CH-4), 11.64 (br s, 1H, OH), 12.31 (br s, 1H, NH). ¹³C NMR (DMSO-*d*₆, HMQC, HMBC): $\delta = 112.44$ (C-7), 117.13 (C-3'), 117.54 (C-1'), 119.66 (C-5'), 123.19 (C-3a), 123.42 (C-5), 126.41 (C-4), 128.02 (C-3'', C-5''), 128.55 (C-2'', C-6''), 130.94 (C-6'), 131.12 (C-6), 131.42 (C-4''), 131.91 (C-3), 134.59 (C-4'), 146.13, 146.58 (C-2, C-1''), 152.68 (C-7a), 157.04 (C2'), 164.96 (CO), 213.25 (CS). MS (EI-HRMS): m/z (%) = 373.08025 (27) (M⁺)(C₂₂H₁₅NO₃S requires 373.07725), 357.08539 (2)(M-O)⁺(C₂₂H₁₅NO₂S requires 357.08234), 340.09878 (48)(M-SH)⁺ (C₂₂H₁₄NO₃ requires

340.09735), 252.05146 (100)(M-C₇H₅O₂)⁺ (C₁₅H₁₀NOS requires 252.0483) (C₁₅H₁₀NO₃ requires 252.06605), 237.07804 (4)(M-C₇H₄OS)⁺ (C₁₅H₁₁NO₂ requires 237.07896) (C₁₅H₉OS requires 237.0374), 220.07348 (4), 121.02781 (52)(C₇H₅O₂ requires 121.02895)(C₇H₅S requires 121.0112), 93.03464 (11)(C₆H₅O requires 93.03404). MS (ESI-HRMS)(positive): *m/z* = 374.08442 (M+H)⁺ (C₂₂H₁₆NO₃S requires 374.08509). Anal. Calcd for C₂₂H₁₅NO₃S: C, 70.76; H, 4.05; N, 3.75. Found: C, 70.68; H, 4.11, N, 3.88.

N-[2-(4-Chlorothiobenzoyl)benzo[*b*]furan-3-yl]-2-hydroxybenzamide (6b)

Starting from **4b** (100 mg, 0.246 mmol). Yield 64 mg (64%). dark brown crystals (AcOH); mp 186-190 °C. IR (KBr): ν = 1655, 1592 cm⁻¹. ¹H NMR (DMSO-*d*₆): δ = 7.03-8.14 (m, 12H, arom.), 11.70 (s, 1H, OH), 12.35 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 113.19, 117.86, 118.24, 120.39, 123.86, 124.21, 128.81, 131.02, 131.64, 132.04, 135.34, 137.04, 145.32, 147.27, 153.53, 157.73, 165.96 (CO), 213.67 (CS). MS (EI): *m/z* (%) = 407 (M⁺, 10), 391 (M-O)⁺ (7), 374 (M-SH)⁺ (19), 286 (M-C₇H₅O₂)⁺ (47), 271 (M-C₇H₄OS)⁺ (15), 155 (C₇H₄ClS)⁺ (7), 139 (C₇H₄ClO)⁺ (5), 121 (C₇H₅O₂)⁺ (100), 93 (C₆H₅O)⁺ (26). Anal. Calcd for C₂₂H₁₄NO₃ClS: C, 64.79; H, 3.46, N, 3.43. Found: C, 64.66; H, 3.50, N, 3.56.

N-[2-(3-Nitrothiobenzoyl)benzo[*b*]furan-3-yl]-2-hydroxybenzamide (6c)

Starting from **4c** (100 mg, 0.239 mmol). Yield 53 mg (53%). dark brown crystals (AcOH); mp 235-237 °C. IR (KBr): ν = 1660, 1594 cm⁻¹. ¹H NMR (DMSO-*d*₆): δ = 7.03-8.51 (m, 12H, arom.), 11.70 (s, 1H, OH), 12.32 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 112.48, 117.06, 117.35, 119.62, 122.75, 123.57, 125.15, 126.61, 129.57, 130.85, 131.68, 134.29, 134.65, 146.67, 147.35, 153.17, 156.92, 164.87, 208.80. MS (EI): *m/z* (%) = 418 (M⁺, 27), 402 (M-O)⁺ (7), 385 (M-SH)⁺ (28), 298 (M-C₇H₄O₂)⁺ (80), 297 (M-C₇H₅O₂)⁺ (40), 282 (M-C₇H₄OS)⁺ (21), 251 (16), 121 (C₇H₅O₂)⁺ (100), 150 (C₇H₄NO₃)⁺ (5), 93 (C₆H₅O)⁺ (17). Anal. Calcd for C₂₂H₁₄N₂O₅S: C, 63.15; H, 3.37; N, 6.69. Found: C, 63.13; H, 3.42; N, 6.57.

N-[2-(Naphthalene-2-carbothieryl)benzo[*b*]furan-3-yl]-2-hydroxybenzamide (6d)

Starting from **4d** (100 mg, 0.236 mmol). Yield 72 mg (72%). dark brown crystals (AcOH); mp 190-192 °C. IR (KBr): ν = 1655, 1592 cm⁻¹. ¹H NMR (DMSO-*d*₆): δ = 7.00-8.37 (m, 15H, arom.), 11.73 (s, 1H, OH), 12.35 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 113.21, 117.82, 118.22, 120.33, 124.06, 124.15, 126.70, 127.03, 127.73, 128.18, 128.34, 128.94, 129.48,

130.26, 131.58, 131.70, 132.40, 132.62, 134.82, 135.25, 144.08, 147.61, 153.46, 157.78, 165.73 (CO), 213.61 (CS). MS (EI): m/z (%) = 423 (M^+ , 25), 407 ($M-O$)⁺ (8), 390 ($M-SH$)⁺ (37), 302 ($M-C_7H_5O_2$)⁺ (100), 287 ($M-C_7H_4OS$)⁺ (9), 286 ($M-C_7H_5OS$)⁺ (9), 270 (13), 269 (13), 171 ($C_{11}H_7S$)⁺ (7), 121 ($C_7H_5O_2$)⁺ (43), 93 (C_6H_5O)⁺ (15). Anal. Calcd for $C_{26}H_{17}NO_3S$: C, 73.74, H, 4.05; N, 3.31. Found: C, 73.70; H, 4.03, N, 3.33.

***N*-[2-(Thiophene-2-carbothioyl)benzo[*b*]furan-3-yl]-2-hydroxybenzamide (6e)**

Starting from **4e** (100 mg, 0.264 mmol). In exception from the general procedure the mixture was refluxed for 20 min. Yield 73 mg (73%). dark brown crystals (AcOH); mp 145-154 °C. IR (KBr): ν = 1654, 1594 cm^{-1} . ¹H NMR (DMSO-*d*₆): δ = 6.98-8.23 (m, 11H, arom.), 11.72 (s, 1H, OH), 12.37 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 113.13, 117.88, 119.91, 120.43, 124.14, 124.29, 126.91, 129.59, 131.54, 131.72, 133.18, 135.27, 135.82, 137.34, 140.51, 145.16, 152.85, 157.77, 165.37 (CO), 196.90 (CS). MS (EI-HRMS): m/z (%) = 379.03252 (37)(M^+) ($C_{20}H_{13}NO_3S_2$ requires 379.03368), 363 ($M-O$)⁺ (5), 346.05135 (19)($M-SH$)⁺ ($C_{20}H_{12}NO_3S$ requires 346.0493), 258.00084 (100)($M-C_7H_5O_2$)⁺ ($C_{13}H_8NOS_2$ requires 258.00473), 243 (5) ($M-C_7H_4OS$)⁺, 226 (8), 126.96498 (8)($C_5H_3S_2$)⁺, ($C_5H_3NS_2$ requires 126.96762), 121.02518 (55)($C_7H_5O_2$)⁺ (requires 121.02895), 110.98733 (8)(C_5H_3OS)⁺ (requires 110.99046), 93 (C_6H_5O)⁺ (17). Anal. Calcd for $C_{20}H_{13}NO_3S_2$: C, 63.31, H, 3.45, N, 3.69. Found. C, 63.31; H, 3.42; N, 3.71.

(3-Aminobenzo[*b*]furan-2-yl)phenylmethanone (8)

The preparation was carried out as described in the literature.¹⁹ light yellow crystals (EtOH); mp 124-126 °C (lit.,¹⁹ 125-126 °C). IR (KBr): ν = 3380, 3275, 1620 cm^{-1} . ¹³C NMR (DMSO-*d*₆): δ = 112.30, 120.91, 122.22, 128.31, 128.71, 130.21, 131.47, 133.63, 138.06, 143.56, 154.22, 180.78 (CO). Anal. Calcd for $C_{15}H_{11}NO_2$: C, 75.94; H, 4.67; N, 5.90. Found: C, 75.93; H, 4.58, N, 5.81.

***N*-(2-Benzoylbenzo[*b*]furan-3-yl)-2-hydroxybenzamide (9)**

A) To a stirred solution of **4a** (100 mg, 0.268 mmol) in a mixture of MeOH (1 mL) and 5M NaOH (1 mL) was added H_2O_2 -solution (30%)(1 mL). After cooling to rt the solution was concentrated and acidified with 5M HCl. The precipitate was purified by PLC (Merck, PLC plates 20x20 mm, silica gel 60 F254, 2 mm, toluene). Yield 70 mg (73%).

B) Analogous to method A, starting from **6a** (100 mg, 0.268 mmol). Yield 77 mg (80%).

C) To a stirred solution of **8** (100mg, 0.42 mmol) in pyridine (1 mL) 2-acetoxybenzoylchloride (0.33 g, 1.66 mmol) was added. After stirring for 2 h at rt the mixture was poured into water (3mL) and the solution was brought to a pH of 9 by addition of 1M NaOH. The mixture was heated up to 90 °C for 2 min. After cooling to rt the oily precipitate was dissolved in a 0.5 M NaOMe-solution in MeOH (1 mL). The product was precipitated again by addition of water and was purified by PLC according to method A. Yield 65 mg (68%). yellow needles (MeCN); mp 173-175 °C. IR (KBr): $\nu = 1645, 1600 \text{ cm}^{-1}$. $^1\text{H NMR}$ (DMSO- d_6 , H-COSY): $\delta = 6.30$ (br dd, $J = 7.2, 7.2 \text{ Hz}$, 1H, CH-5'), 6.64 (br d, $J = 7.8 \text{ Hz}$, 1H, CH-3'), 7.06 (br dd, $J = 7.2, 7.2 \text{ Hz}$, 1H, CH-4'), 7.32 (dd, $J = 7.2, 7.2 \text{ Hz}$, 1H, CH-5), 7.54 (m, 3H, CH-3'', CH-5'', CH-6), 7.61 (m, 2H, CH-7, CH-4''), 7.77 (br m, 1H, CH-6'), 8.05 (d, $J = 7.2 \text{ Hz}$, 2H, CH-2'', CH-6''), 8.33 (d, $J = 7.4 \text{ Hz}$, 1H, CH-4). The signals of OH and NH do not appear. This seems to be due to tautomerism connected with an H/D-exchange. $^{13}\text{C NMR}$ (DMSO- d_6 , HMQC, HMBC): $\delta = 110.73$ (br, C-5'), 111.90 (C-7), 117.87 (br, C-1'), 121.12 (br, C-3'), 122.29 (C-5), 123.50 (C-3a), 126.51 (C-4), 128.19 (C-6, C-3'', C-5''), 128.59 (C-3), 129.10 (C-2'', C-6''), 129.69 (C-6'), 132.09 (C-4''), 132.31 (C-4'), 137.85 (C-1'), 139.14 (C-2), 153.74 (C-7a), 165.75 (NHCO), 169.67 (br, C-2'), 183.24 (C₆H₅-CO). MS (EI): m/z (%) = 357 (M⁺, 24), 237 (M-C₇H₄O₂)⁺ (100), 121 (C₇H₅O₂)⁺ (64), 105 (C₇H₅O)⁺ (15), 93 (C₆H₅O)⁺ (22). Anal. Calcd for C₂₂H₁₅NO₄: C, 73.94; H, 4.23, N, 3.92. Found: C, 73.78; H, 4.30, N, 4.00.

2-Hydroxythiobenzamide (10)

The preparation was carried out as described in the literature.²⁰ light yellow crystals (EtOH); mp 119-120 °C (lit.,²⁰ 119-120 °C). IR (KBr): $\nu = 3406, 3300, 3203, 1640 \text{ cm}^{-1}$. $^{13}\text{C NMR}$ (DMSO- d_6): $\delta = 117.38, 118.67, 122.87, 129.98, 132.87, 156.24, 196.90$ (CS). Anal. Calcd for C₇H₇NS: C, 61.28; H, 5.14, N, 10.21. Found: C, 61.43; H, 5.19, N, 10.18.

2-Hydroxybenzamide (11)

Commercially available product, purchased from Acros Organics; B 2440 Gel, Belgium. IR (KBr): $\nu = 3396, 3190, 1674 \text{ cm}^{-1}$. $^{13}\text{C NMR}$ (DMSO- d_6): $\delta = 114.56, 117.61, 118.05, 128.29, 134.42, 161.35, 172.42$ (CO).

ACKNOWLEDGMENTS

The author would like to thank Dr. Hofmann for the MS spectra, Dr. Hennig and Mrs. Ortwein

for recording the NMR spectra and Dr. Rattay for proof reading of the manuscript.

REFERENCES

1. M. Negwer and H. G. Scharnow, *Organic-Chemical Drugs and Their Synonyms*, Wiley-VCH Weinheim, New York 2001, Drug-No.: 1945, 3755, 3760, 3764, 3769, 3780, 3790, 3842, 3845, 4350, 4393, 5085, 5347, 8310, 8314.
2. R. Stanislav, P. Hezky, P. Konvicka, and I. Krejci, *Coll. Czech. Chem. Commun.*, 2000, **65**, 1093.
3. G. Braeunlich, R. Fischer, M. Essayed, R. Henning, M. Sperzel, K. H. Schlemmer, U. Nielsch, S. Tudhope, and G. Sturton, *Eur. Pat. Appl.* EP 731099, 1996; *Eur. Pat. Appl.*, 731099, 11 Sep 1996 (*Chem. Abstr.*, 1996, **125**, 247609g).
4. D. T. Connor, W. A. Cetenko, P. Unangst, and E. A. Johnson, *Eur. Pat. App.*, 187487, 16 Jul 1986 (*Chem. Abstr.*, 1986, **105**, 226335).
5. D. Briel and S. Leistner, *Pharmazie*, 1994, **49**, 285.
6. S. Leistner, G. Wagner, and M. Ackermann, *Z. Chem.*, 1977, **17**, 223.
7. D. Briel, S. Leistner, and K. Drößler, *Arch. Pharm.*, 1991, **324**, 959.
8. D. Briel and S. Leistner, *Arch. Pharm.*, 1994, **327**, 389.
9. R. Röhrkasten and M. Konrad, in *Houben-Weyl*, 4th ed., Vol. E6b1, ed. by R. P. Kreher, Thieme, Stuttgart, 1994, **48** (review) and literature cited therein.
10. R. A. Smith, J. Chen, M. M. Mader, I. Muegge, U. Moehler, S. Katti, D. Marrero, W. G. Stirtan, D. R. Weaver, H. Xiao, and W. Carley, *Bioorganic & Medicinal Chemistry Letters*, 2002, **12**, 2875.
11. C. Paizs, M. Tosa, C. Majdik, P. Moldovan, L. Novak, P. Kolonits, A. Marcovici, and F. D. Irimie, *Tetrahedron Asymmetry*, 2003, **14**, 1495.
12. J. Habermann, S. V. Ley, and R. J. Smits, *J. Chem. Soc., Perkin Trans. 1*, 1999, 2421.
13. S. Radl, P. Konvicki, and P. J. Vachal, *J. Heterocycl. Chem.*, 2000, **37**, 855.
14. I. Shibuya, *Bull. Chem. Soc. Jpn.*, 1979, **52**, 3767.
15. R. R. Schmidt, *Synthesis*, 1972, 333 and literature cited therein.
16. M. Sainsbury in *Comprehensive Heterocyclic Chemistry*, Vol. 3, ed. by A. R. Katritzky, C. W. Rees, A. J. Boulton, and A. McKillop, Pergamon, Oxford, 1984, 995 and literature cited therein.
17. T. E. Glotowa, A. C. Nachmanowitsch, and N. C. Mabarakschina, *Khim. Geter. Soed.*, 1988, 705.
18. E. Pretsch, T. Clerc, J. Seibl, and W. Simon, *Tabellen zur Strukturaufklärung organischer Verbindungen mit spektroskopischen Methoden*, Springer Verlag, Berlin,

Heidelberg, 1990.

19. K. Gewalt and H. J. Jansch, *J. Prakt. Chem.*, 1973, **315**, 779.
20. G. Wagner, D. Singer, and W. Weuffen, *Pharmazie*, 1966, **21**, 166.